Explore
Validate
Learn
Western blot
Other assayAntibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MA5-24103 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- MYOCD Monoclonal Antibody (355521)
- Antibody type
- Monoclonal
- Antigen
- Recombinant full-length protein
- Description
- Reconstitute at 0.5 mg/mL in sterile PBS. Endoxin level is
- Reactivity
- Human, Mouse
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- 355521
- Vial size
- 100 µg
- Concentration
- 0.5 mg/mL
- Storage
- -20°C, Avoid Freeze/Thaw Cycles
Submitted references YTHDC2-Mediated circYTHDC2 N6-Methyladenosine Modification Promotes Vascular Smooth Muscle Cells Dysfunction Through Inhibiting Ten-Eleven Translocation 2.
Yuan J, Liu Y, Zhou L, Xue Y, Lu Z, Gan J
Frontiers in cardiovascular medicine 2021;8:686293
Frontiers in cardiovascular medicine 2021;8:686293
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 5 CircYTHDC2 negatively regulates TET2. (A) The schematic diagram of TET2-WT or TET2-Mut luciferase reporter gene. The wild type motifs were indicated by green and the mutant motif was indicated by red. A7R5 cells were transfected with TET2-WT or TET2-Mut, combined with circYTHDC2 siRNA. The cells transfected with scramble control were used as control. Luciferase report gene assay were performed to measure the relative luciferase activity. (B) Relative enrichment representing TET2 and circYTHDC2 RNA levels associated with circYTHDC2 junction compared to control. (C) qRT-PCR analysis for the expression of TET2 after high glucose treatment in A7R5 cells. (D) western blotting analysis of TET2 expression after high glucose treatment in A7R5 cells. (E) qRT-PCR analysis for the expression of TET2 after circYTHDC2 siRNA transfection in A7R5 cells. (F) western blotting analysis of TET2 expression after circYTHDC2 siRNA transfection in A7R5 cells. (G) western blotting analysis of TET2 expression after TET2 siRNA transfection in A7R5 cells. (H) western blotting analysis for the expression of MYODC, SRF and KLF4 in A7R5 cells after circYTHDC2 siRNA transfection alone, or combined with TET2 siRNA transfection. (I) qRT-PCR analysis for the expression of TET2 after circYTHDC2 transfection in A7R5 cells. (J) western blotting analysis of TET2 expression after circYTHDC2 transfection in A7R5 cells. (K) western blotting analysis of TET2 expression after TET2 transfection in A7R5 cells.
